Sera Prognostics Reports 2025 Financial Results and Strategic Progress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 18 2026
0mins
Source: PRnewswire
- Financial Overview: In Q4 2025, Sera Prognostics reported revenue of $10,000, a 58.3% decline from $24,000 in Q4 2024, indicating challenges in the commercialization process, while total annual revenue reached $81,000, up 5.2% from $77,000 in 2024, reflecting gradual market acceptance improvements.
- Cost Control: Total operating expenses for Q4 2025 were $9.0 million, down 4.3% from $9.4 million in Q4 2024, with R&D expenses at $3.2 million, slightly higher than last year's $3.1 million, indicating a balance between R&D and market promotion to support future growth.
- Net Loss: The net loss for Q4 2025 was $7.9 million, an 8.2% decrease from $8.6 million in Q4 2024, demonstrating ongoing efforts in capital management despite pressures on revenue expansion.
- Cash Flow and Financing: As of December 31, 2025, the company had approximately $95.8 million in cash and cash equivalents, expected to fund significant market adoption and commercial milestones through 2028, enhancing investor confidence in future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SERA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SERA
Wall Street analysts forecast SERA stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.090
Low
5.00
Averages
5.00
High
5.00
Current: 2.090
Low
5.00
Averages
5.00
High
5.00
About SERA
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sera Prognostics Secures $10.4 Million Research Grant for Maternal Health
- Research Funding: Sera Prognostics Inc. has secured up to $10.4 million in funding to develop a novel point-of-care diagnostic test aimed at improving delivery safety, led by UC San Diego, showcasing the company's innovative potential in maternal health.
- Technical Collaboration: The project collaborates with Allegro MicroSystems, focusing on assessing fetal hypoxia risk from small maternal blood samples, aiming to provide timely, objective information to clinicians, thereby enhancing maternal and neonatal health outcomes and reflecting Sera's strategic positioning in precision medicine.
- Proactive Decision-Making: CEO Zhenya Lindgardt emphasized that this research signifies a shift in maternal health from reactive to proactive risk identification, aligning with the company's mission to deliver more precise insights that improve outcomes for mothers and babies.
- Market Potential: With growing interest in innovative diagnostic approaches, Sera's research is expected to enhance decision-making quality during labor while potentially reducing unnecessary interventions, further solidifying its leadership position in the maternal health market.
See More
Illinois Legislation Advances Early Identification of Preterm Birth Risk
- Legislative Advancement: Illinois has amended its Public Aid Code to mandate Medicaid coverage for proteomic blood tests that identify and manage spontaneous preterm birth risk, which is expected to significantly improve maternal health outcomes.
- Preterm Birth Statistics: In 2024, Illinois recorded 13,042 preterm births, with 250 babies born preterm each week, highlighting the urgency of legislative action to mitigate this leading cause of maternal and neonatal complications.
- Economic Implications: Preterm birth imposes a substantial financial burden on Medicaid programs, and by expanding access to effective risk assessment tools, the legislation aims to enhance outcomes for approximately 50,000 Medicaid births annually, potentially reducing long-term healthcare costs.
- Innovative Testing: Sera's PreTRM® Test is the only broadly validated blood-based test that provides individualized risk predictions for spontaneous preterm birth during weeks 18 to 20 of pregnancy, facilitating more informed clinical decisions and improving the quality of care for pregnant individuals.
See More
Sera Prognostics Q1 2026 Earnings Call Highlights
- Partnership Program Expansion: Sera Prognostics launched its third partnership program in Q1, expected to reach over 350 providers, further advancing its commercial strategy and expanding access to PreTRM.
- Increased Payer Engagement: The company is currently engaged with 13 payers across 15 states, indicating a concentrated strategy for driving implementation and adoption, although revenue may remain modest and uneven in the short term.
- Cost Realignment Benefits: Following a comprehensive business review, the company expects to reduce base operating expenses by nearly $10 million annually, which will help sustain cash flow and capital expenditure needs through 2029.
- Revenue Performance Analysis: Revenue for the quarter was $14,000, significantly down from $38,000 in Q1 2025, reflecting ongoing challenges in driving reimbursement and awareness initiatives.
See More
Sera Prognostics 2025 Financial Report Analysis
- Revenue Fluctuation: In Q4 2025, revenue dropped to $10,000 from $24,000 in Q4 2024, indicating significant volatility at this early commercial stage, which may affect investor confidence.
- High Operating Expenses: Operating expenses for Q4 stood at $9 million, down from $9.4 million in the previous year, yet still reflect the high costs associated with commercialization efforts, potentially limiting profitability improvements.
- Net Loss Improvement: The net loss for Q4 2025 was $7.9 million, an improvement from $8.6 million in 2024; however, ongoing losses pose challenges to the company's financial health, impacting future funding capabilities.
- Strong Cash Reserves: By the end of 2025, the company held $95.8 million in cash equivalents, expected to fund operations through 2028, providing essential financial support for its commercialization strategy and enhancing market confidence.
See More
Sera Prognostics Q4 2025 Earnings Call Insights
- Financial Overview: In Q4 2025, Sera Prognostics reported revenue of $10,000, down from $24,000 in Q4 2024, although operating expenses decreased from $9.4 million to $9 million, reflecting efforts in financial discipline.
- Leadership Enhancement: The company appointed Lee Anderson as Chief Commercial Officer and Dr. Tiffany Inglis as Chief Medical Officer, aiming to strengthen market outreach and medical affairs to drive the implementation of the PRIME project and increase market share in maternal health.
- Market Expansion Plans: Sera aims to engage in active discussions across 15 to 17 states by the end of 2026 and plans to increase the number of partner programs to cover 58% to 60% of U.S. births, indicating a proactive approach in its commercialization strategy.
- Future Outlook: Management expects gradual revenue growth as partner programs mature and emphasizes maintaining financial discipline to support significant milestones through 2028, ensuring effective capital utilization.
See More
Sera Prognostics Q4 2025 Earnings Call Transcript
See More
Sera Prognostics Secures $10.4 Million Research Grant for Maternal Health
- Research Funding: Sera Prognostics Inc. has secured up to $10.4 million in funding to develop a novel point-of-care diagnostic test aimed at improving delivery safety, led by UC San Diego, showcasing the company's innovative potential in maternal health.
- Technical Collaboration: The project collaborates with Allegro MicroSystems, focusing on assessing fetal hypoxia risk from small maternal blood samples, aiming to provide timely, objective information to clinicians, thereby enhancing maternal and neonatal health outcomes and reflecting Sera's strategic positioning in precision medicine.
- Proactive Decision-Making: CEO Zhenya Lindgardt emphasized that this research signifies a shift in maternal health from reactive to proactive risk identification, aligning with the company's mission to deliver more precise insights that improve outcomes for mothers and babies.
- Market Potential: With growing interest in innovative diagnostic approaches, Sera's research is expected to enhance decision-making quality during labor while potentially reducing unnecessary interventions, further solidifying its leadership position in the maternal health market.
See More
Illinois Legislation Advances Early Identification of Preterm Birth Risk
- Legislative Advancement: Illinois has amended its Public Aid Code to mandate Medicaid coverage for proteomic blood tests that identify and manage spontaneous preterm birth risk, which is expected to significantly improve maternal health outcomes.
- Preterm Birth Statistics: In 2024, Illinois recorded 13,042 preterm births, with 250 babies born preterm each week, highlighting the urgency of legislative action to mitigate this leading cause of maternal and neonatal complications.
- Economic Implications: Preterm birth imposes a substantial financial burden on Medicaid programs, and by expanding access to effective risk assessment tools, the legislation aims to enhance outcomes for approximately 50,000 Medicaid births annually, potentially reducing long-term healthcare costs.
- Innovative Testing: Sera's PreTRM® Test is the only broadly validated blood-based test that provides individualized risk predictions for spontaneous preterm birth during weeks 18 to 20 of pregnancy, facilitating more informed clinical decisions and improving the quality of care for pregnant individuals.
See More
Sera Prognostics Q1 2026 Earnings Call Highlights
- Partnership Program Expansion: Sera Prognostics launched its third partnership program in Q1, expected to reach over 350 providers, further advancing its commercial strategy and expanding access to PreTRM.
- Increased Payer Engagement: The company is currently engaged with 13 payers across 15 states, indicating a concentrated strategy for driving implementation and adoption, although revenue may remain modest and uneven in the short term.
- Cost Realignment Benefits: Following a comprehensive business review, the company expects to reduce base operating expenses by nearly $10 million annually, which will help sustain cash flow and capital expenditure needs through 2029.
- Revenue Performance Analysis: Revenue for the quarter was $14,000, significantly down from $38,000 in Q1 2025, reflecting ongoing challenges in driving reimbursement and awareness initiatives.
See More
Sera Prognostics 2025 Financial Report Analysis
- Revenue Fluctuation: In Q4 2025, revenue dropped to $10,000 from $24,000 in Q4 2024, indicating significant volatility at this early commercial stage, which may affect investor confidence.
- High Operating Expenses: Operating expenses for Q4 stood at $9 million, down from $9.4 million in the previous year, yet still reflect the high costs associated with commercialization efforts, potentially limiting profitability improvements.
- Net Loss Improvement: The net loss for Q4 2025 was $7.9 million, an improvement from $8.6 million in 2024; however, ongoing losses pose challenges to the company's financial health, impacting future funding capabilities.
- Strong Cash Reserves: By the end of 2025, the company held $95.8 million in cash equivalents, expected to fund operations through 2028, providing essential financial support for its commercialization strategy and enhancing market confidence.
See More
Sera Prognostics Q4 2025 Earnings Call Insights
- Financial Overview: In Q4 2025, Sera Prognostics reported revenue of $10,000, down from $24,000 in Q4 2024, although operating expenses decreased from $9.4 million to $9 million, reflecting efforts in financial discipline.
- Leadership Enhancement: The company appointed Lee Anderson as Chief Commercial Officer and Dr. Tiffany Inglis as Chief Medical Officer, aiming to strengthen market outreach and medical affairs to drive the implementation of the PRIME project and increase market share in maternal health.
- Market Expansion Plans: Sera aims to engage in active discussions across 15 to 17 states by the end of 2026 and plans to increase the number of partner programs to cover 58% to 60% of U.S. births, indicating a proactive approach in its commercialization strategy.
- Future Outlook: Management expects gradual revenue growth as partner programs mature and emphasizes maintaining financial discipline to support significant milestones through 2028, ensuring effective capital utilization.
See More
Sera Prognostics Q4 2025 Earnings Call Transcript
See More
